MAP3K14 and coronary artery disorder: Recent meta-analyses (139–142) have shown that colchicine positively reduces the incidence of MACE, MI, stroke, and revascularization and decreases cardiovascular events, inflammatory markers, hs-CRP, and IL-6 in patients with coronary artery disease.